Buy Tata Chemicals, target of Rs 466: Emkay

Published on Sat, Jun 28, 2008 at 11:56 |  Source : Moneycontrol.com

Updated at Sat, Jun 28, 2008 at 12:00  

24338 Investors following Tata Chemicals. Share this News with them.
0
0
Share on Tumblr

RELATED NEWS

Emkay Research has maintained its buy rating on Tata Chemicals with a target price of Rs 466 in its June 27, 2008 research report. "Tata Chemicals (TCL) Q4FY08 results were below expectations. Net sales declined by 13%YoY to Rs 14.6 billion and EBITDA margins declined by 380 bps to 14.5%. Results were affected due to unsatisfactory performance of the subsidiary BMGL. earnings. PAT (after adjusting for Rs 4.8 billion from profit on sale of investments, Rs 188 million forex loss and Rs 345 million pension liabilities) declined by 45.4% YoY to Rs 751 million."

"As a result we are revising our EPS estimates downward by 17.8% and 11.9% to Rs 33.6 (previous Rs 40.9) and Rs 42.4 (previous Rs 48.1) for FY09E and FY10E, respectively. We are also revising our target price downward by 11.9% to Rs 466 from Rs 529 however our view remains positive on soda ash cycle and we maintain our BUY recommendation on the stock," says Emkay's research report.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

For further details click on attachment......

  

More on Moneycontrol

Trending News

Business News

6 ways to backup mobile data
Forget the IIP: there's free cash oozing out of every pore "Forget the IIP: there's free cash oozing out of every pore "

DLF Says Macro Environment Unfavourable W/High Comm & Labour Inflation

The latest earning numbers FIRST on CNBC-TV18
Videos

Feb 10 2012, 21:39

Tulsian buys steel stocks; negative on sugar, ADAG

- in MARKET OUTLOOK

Feb 10 2012, 21:39

Truck demand sluggish; margins down 80bps: Shriram Trans

- in Results Boardroom

Interviews

Feb 10 2012, 15:43 | Source: CNBC-TV18

Growth in margins sustainable going forward: Shasun Pharma  

Feb 10 2012, 15:35 | Source: CNBC-TV18

Expect Q4 GRMs to be similar to Q3: BPCL  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!

Follow moneycontrol.com